

## Drug Monograph

Drug Name: **Ingrezza<sup>®</sup> (valbenazine) capsule**  
 Drug Class: **CNS: Vesicular Monoamine Transportation 2 (VMAT2) Inhibitors**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Ingrezza is now available as a 60 mg capsule. Previously available as 40 mg and 80 mg capsules.

**Manufacturer:** Distributed by: Neurocrine Biosciences, Inc., San Diego, CA 92130.

**Indications:** Ingrezza is indicated for the treatment of adults with tardive dyskinesia.

**Costs:** \$7,043 per 30 capsules of 60 mg Ingrezza. Wholesale Acquisition Cost

**Summary of Findings:** This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.

**Status Recommendation:**  Clinical Edit  PA Required  
 Open Access  PDL

**Type of PA Criteria:**  Appropriate Indications  Non-Preferred  
 No PA Required  Preferred

Prepared by: April Ash, PharmD.  
 Date: June 18, 2021